SGLT-2 inhibitors were associated with a lower incidence of MACE in patients with CKD, compared with placebo: RR 0.84 (95% CI 0.75–0.94; P = 0.003) (Fig. 3 and Table 3). Here, SLC5A2 is linked to chronic kidney disease.